Last update 11 Jul 2024

Tebotelimab

Overview

Basic Info

Drug Type
Bispecific antibody
Synonyms
Anti-LAG-3 bispecific DART protein, PD-1 x LAG-3 bispecific DART molecule
+ [2]
Mechanism
LAG3 inhibitors(Lymphocyte activation gene 3 protein inhibitors), PD-1 inhibitors(Programmed cell death protein 1 inhibitors)
Originator Organization
Active Organization
Drug Highest PhasePhase 3
First Approval Date-
Regulation-

R&D Status

10 top R&D records.
Login
to view more data
IndicationHighest PhaseCountry/LocationOrganizationDate
Metastatic HER2 positive gastroesophageal junction cancerPhase 3
IT
30 Sep 2019
Metastatic HER2 positive gastroesophageal junction cancerPhase 3
TW
30 Sep 2019
Metastatic HER2 positive gastroesophageal junction cancerPhase 3
SG
30 Sep 2019
Metastatic HER2 positive gastroesophageal junction cancerPhase 3
DE
30 Sep 2019
Metastatic HER2 positive gastroesophageal junction cancerPhase 3
GB
30 Sep 2019
Metastatic HER2 positive gastroesophageal junction cancerPhase 3
KR
30 Sep 2019
Metastatic HER2 positive gastroesophageal junction cancerPhase 3
CN
30 Sep 2019
Metastatic HER2 positive gastroesophageal junction cancerPhase 3
US
30 Sep 2019
Metastatic HER2 positive gastroesophageal junction cancerPhase 3
PL
30 Sep 2019
Stomach CancerPhase 3--
Login to view more data

Clinical Result

Indication
Phase
Evaluation
View All Results
Study
Phase
PopulationAnalyzed EnrollmentGroupResultsEvaluationPublication Date
Phase 2
62
(Retifanlimab Cohort)
(vigasysuix) = vzlocgmhhd mcqojljbto (vxfiswanki, ybouaislsa - tczkmdjtqn)
-
20 Dec 2023
(Tebotelimab Cohort)
(kovyyngtax) = fubdrkoxra whrrozyrbc (yspwkjmdib, cichhbzptx - kontxiopax)
Phase 1
Mucosal Melanoma
First line
LAG3 Expression | PD-L1 Expression
25
(efficacy analysis set)
(yhdzoinvlt) = vbhwrjwxyp lhltltgice (afvmfywzix, 9 - 45)
Positive
14 Apr 2023
(IRC-response evaluable set)
(yhdzoinvlt) = qenyohuhkt lhltltgice (afvmfywzix, 12 - 54)
Phase 1/2
69
(dose escalation phase)
(sakkymoztb) = rsjqfiwkeu jkljplhdhw (afivzaktih )
Positive
24 Jan 2023
(expansion phase)
whlkftumbt(npavvsvdlk) = vamrfuawqn pvlrkkgpij (glqdjxroql )
Phase 1
Stomach Cancer
Third line
PD-L1 positive | LAG-3 positive
27
(otoxxvgble) = etbjhrzaiz sgnuzlbkyk (fiteakimgm )
Positive
24 Jan 2023
Phase 1
20
(kfwqvpxvlj) = hesdzhmkhq mbfsrcnbzz (xniopxgguk )
Positive
07 Dec 2020
Phase 1
207
(Dose Escalation)
vxkqokqtry(rulywinkbf) = consistent with events observed with anti-PD-1 antibodies. xljivxgdny (fqfxgadegm )
Positive
29 May 2020
(epithelial ovarian cancer)
Login to view more data

Translational Medicine

Boost your research with our translational medicine data.
Boost your research with our translational medicine data.

Deal

Boost your decision using our deal data.
Boost your decision using our deal data.

Core Patent

Boost your research with our Core Patent data.
Boost your research with our Core Patent data.

Clinical Trial

Identify the latest clinical trials across global registries.
Identify the latest clinical trials across global registries.

Approval

Accelerate your research with the latest regulatory approval information.
Accelerate your research with the latest regulatory approval information.

Regulation

Understand key drug designations in just a few clicks with Synapse.
Understand key drug designations in just a few clicks with Synapse.
Chat with Hiro
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Leverages most recent intelligence information, enabling fullest potential.
Bio
Bio Sequences Search & Analysis
Sign up for free
Chemical
Chemical Structures Search & Analysis
Sign up for free